Table 1.
Demographic and Clinical Characteristics at the Time of TDF-to-TAF Switch
| All Switches (n = 6451) | Maintained Other ARVs (n = 4328) | |
|---|---|---|
| Months on TDF preswitch, median (IQR) | 29 (14–52) | 28 (14–46) |
| Age, median (IQR), y | 48 (38–55) | 47 (37–54) |
| Female, No. (%) | 1010 (16) | 674 (16) |
| HIV viral load ≥50 copies/mL, No. (%) | 1103 (17) | 620 (14) |
| Hormone use, No. (%) | 554 (8) | 372 (9) |
| Statin use, No. (%) | 1112 (17) | 732 (17) |
| Nonstatin lipid-lowering agenta use, No. (%) | 425 (7) | 267 (6) |
Abbreviations: ARV, antiretroviral; IQR, interquartile range; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
Cholestyramine, ezetimibe, fibrate, niacin, omega-3.